Page 87 - 2019_10 resto del Mondo_web

Immunosuppressive therapy for pediatric aplastic anemia
References
1. Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S119-125.
2. ScheinbergP,WuCO,NunezO,YoungNS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr. 2008;153(6):814-819.
3. Kojima S, Horibe K, Inaba J, et al. Long- term outcome of acquired aplastic anaemia in children: comparison between immuno- suppressive therapy and bone marrow transplantation. Br J Haematol. 2000; 111(1):321-328.
4. Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe aplastic ane- mia in children: bone marrow transplanta- tion from a matched family donor versus immunosuppressive therapy. Haematologica. 2014;99(12):1784-1791.
5. Kamio T, Ito E, Ohara A, et al. Relapse of aplastic anemia in children after immuno- suppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group. Haematologica. 2011;96(6):814- 819.
6. Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alterna- tive donor as second-line treatment for chil- dren with severe and very severe aplastic anemia. Blood. 2008;111(3):1054-1059.
7. Garanito MP, Carneiro JD, Odone Filho V, Scheinberg P. Outcome of children with severe acquired aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine A. J Pediatr (Rio J). 2014; 90(5):523-527.
8. Dufour C, Pillon M, Passweg J, et al. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014;99(10):1574-1581.
9. Dufour C, Pillon M, Socie G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and
paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169(4):565- 573.
10. Scheinberg P, Nunez O, Weinstein B, Biancotto A, Wu CO, Young NS. Horse ver- sus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430-438.
11. Williams DA, Bennett C, Bertuch A, et al. Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): An initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC). Pediatr Blood Cancer. 2014;61(5):869-874.
12. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med. 2017;376(16):1540-1550.
13. Alter BP, Baerlocher GM, Savage SA, et al. Very short telomere length by flow fluores- cence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2007;110(5):1439-1447.
14. Camitta BM, Storb R, Thomas ED. Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306(11):645-652.
15. Camitta BM, Storb R, Thomas ED. Aplastic anemia (second of two parts): pathogene- sis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306(12):712-718.
16. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylpred- nisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324(19):1297-1304.
17. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic ane- mia. Blood. 1995;85(11):3058-3065.
18. Fuhrer M, Burdach S, Ebell W, et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group. Klin Padiatr. 1998; 210(4):173-179.
19. Kojima S, Hibi S, Kosaka Y, et al.
Immunosuppressive therapy using antithy- mocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000; 96(6):2049-2054.
20. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stim- ulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95(6):1931-1934.
21. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leuko- cytes with hematopoietic relapse, malig- nant transformation, and survival in severe aplastic anemia. JAMA. 2010;304(12):1358- 1364.
22. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37(1):91-101.
23. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289 (9):1130-1135.
24. Samarasinghe S, Steward C, Hiwarkar P, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immuno- suppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol. 2012;157(3):339-346.
25. Anderlini P, Wu J, Gersten I, et al. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015;2(9):e367-375.
26. Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus immuno- suppressive therapy in patients with acquired severe aplastic anemia. Int J Hematol. 2016;104(2):168-174.
haematologica | 2019; 104(10)
1983